AMBRISENTAN: THE POSSIBILITY OF THE TREATMENT FOR PULMONARY ARTERIAL HYPERTENSION WITH THE SELECTIVE BLOCKADE OF THE ENDOTHELIN SYSTEM

The optimization of the drug therapy for pulmonary arterial hypertension (PAH) associated with the introduction into clinical practice of highly effective drugs of pathogenetic action affecting the main targets of disease - activating the endothelin (ET-1) system, deficiency of endogenous prostacyclin and nitric oxide. The role of ET-1 in the pathogenesis of PAH due to powerful vasoconstrictive action, the ability to induce cell proliferation and differentiation, production of growth factors, cytokines, biologically active substances. Endothelin receptor antagonists (ERAs) - is the most important class of PAH- specific therapies, including two drugs - nonselective ERA bosentan and selective ERA - ambrisentan. The evidence base related to the application ambrisentan in PAH includes three key studies: testing of different dose regimes of the drug; 2 randomized, placebo-controlled, double-blind clinical studies and the study with replacement of ERAs on ambrisentan in patients intolerant other ERAs . In the study on ambrisentan dosage regimes testing increase of the distance in 6 - minute walk distance (6-MWT) was dose-dependent. Using the drug in doses ranging from 1mg to 10 mg to 12 wks. there achieved a significant increase in 6-MWT distance of 33.9 m with 1mg dose (p=0.003) to 38.1m with 5mg (p=0.001). In two 12wk randomized, placebo-controlled studies ARIES- 1 and ARIES- 2 (Ambrisentan in PAH-a phase III, Randomized, Double-blind, placebo-controlled, multicenter, Efficacy Study of ambrisentan on Subjects with pulmonary arterial hypertension) the treatment with ambrisentan resulted to the significant increase of exercise tolerance according to 6-MWT from 22 m to 59 m when using the dose of 2.5mg (p = 0.022) and 10mg (p < 0.001), respectively. Ambrisentan treatment helped to reduce the need for lung transplantation, atrial septostomy, hospitalization for PAH progression. Achieved improvement was maintained for 2-year treatment with ambrisentan. Ambrisentan therapy was well tolerated. By 12 weeks the frequency of transaminases and bilirubin elevations was significantly lower with ambrisentan than for placebo group (0.8% versus 2.3%, respectively). Long-term follow up in the open study in 383 patients treated with ambrisentan, 95% of patients were alive at 1 year and 94 % of patients continued the treatment. Patients with adverse events when receiving bosentan or sitaksentan after translation to ambrisentan had no increase of liver transaminases. Thus, treatment with ambrisentan in PAH pts. resulted in the improvement of clinical symptoms and hemodynamic parameters, the increase in exercise tolerance and the prolongation of the time to the development of clinical deterioration. Favorable effects of long-term therapy with ambrisentan are shown for at least 2 years. In 2012 ambrisentan was approved by the Russian National Pharmacological Committee for the treatment of patients with PAH (Functional Classes II-III) at the dose of 5 mg and 10 mg PO.

лёгочная артериальная гипертензия, эндо-телин-1, антагонисты рецепторов эндотелина, амбризентан, pulmonary arterial hypertension, endothelin-1, endothelin receptor antagonists, ambrisentan

1. Российские рекомендации по диагностике и лечению лёгочной гипертензии, 2007.

2. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology and the European Respiratory Society, endorsed by the International Society of Heart and Lung Transplantation.// Eur. Heart J 2009; 30 (20): 493-537.

3. Simonneau G., Robbins I., Beghetti M., et al. Updated clinical classification of pulmonary hypertension.// J Am Coll Cardiol 2009;54: S43-54.

4. Dupuis J, Hoeper M.M. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008; 31: 407-415.

5. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in pulmonary hypertension. NEngl J Med 2000;343:1342.

6. Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008; 31(4): 881-901.

7. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.

8. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415.

9. Galie N, Manes A, Branzi A. The endothelin system in pulmonary hypertension. Cardiovasc Res 2004; 61: 227237.

10. Ito H, Hirata Y, Hiroe M, et al. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ Res 1991; 69:209-215.

11. Stewart DJ, Levy RD, Cernacek P. Increased plasma endothelin-1 in primary pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991;114:464-469.

12. Sauvageau S, Thorin E, Caron A, Dupuis J. Endothelin-1-induced pulmonary vasoreactivity is regulated by ET(A) and ET(B) receptor interactions. J Vasc Res 2007;44:375-381.

13. Masaki T. Possible role of endothelin in endothelial regulation of vascular tone.Annu Rev Pharmacol Toxicol 1995;35:235-255.

14. Opitz CF., Ewert R, Kirch W, Pittrow D. Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur Heart J doi:10.1093/eurheartj/ehn234.

15. Clozel M, Gray GA. Are there different ETB receptors mediating constriction and relaxation? J Cardiovasc Pharmacol 1995;26(Suppl. 3):S262-S264.

16. Dupuis J, Cernacek P, Tardif JC, et al. Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. Am Heart J 1998;135:614-620.

17. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328:1732-1739.

18. Davie N, Haleen SJ, Upton PD, et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002;165:398-405.

19. Kahaleh MB. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum 1991;34: 978-983.

20. Cheng JW. Ambrisentan for the Management of Pulmonary Arterial Hypertension. Clinical Therapeutics 2008; Vol. 30 (5):825-832.

21. Rubin LJ, Galie N, Badesch DB, et al. Ambrisentan improves exercise capacity and clinical measures in pulmonary arterial hypertension. Am J Crit Care Med 2004; 169: A210.

22. D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-349.

23. McGoon M, Frost A, Oudiz R, et al. Ambrisentan rescue therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxentan due to liver function abnormalities. Chest 2006;254S.

24. Oudiz R, Torres F, Frost A, et al. ARIES-1: a placebocontrolled, efficacy and safety study of ambrisentan in patients with pulmonary arterial hypertension. Chest 2006;130:121S.

25. Olschewski H, Galie N, Ghofrani H et al. Ambrisentan improves exercise capacity and time to clinical worsening in patients with pulmonary arterial hypertension: Results of the ARIES-2 study. Proc Am Thorac Soc 2006;3:A728.

26. Oudiz R, Badesch D, Rubin L. ARIES-E: Long-term safety and efficacy of ambrisentan in pulmonary arterial hypertension. Chest 2007;132:474a.

27. Elshaboury SM, Anderson JR. Ambrisentan for the treatment of pulmonary arterial hypertension: improving outcomes. Patient Preference and Adherence 2013;7:401-409.

28. Рациональная фармакотерапии сердечно-сосудистых заболеваний под ред. Е.И.Чазова, Ю.А.Карпова. 2014. Глава "Антагонисты рецепторов эндотелина".стр.281-290.

29. FDA Drug Safety Communication: Liver injury warning to be removed from Letairis (ambrisentan) tablets.http://www. fda.gov/Drugs/DrugSafety/ucm245852.htm.